Maria Ripps, an analyst from Canaccord Genuity, maintained the Buy rating on Hims & Hers Health (HIMS – Research Report). The associated price target remains the same with $68.00.
Maria Ripps has given her Buy rating due to a combination of factors that highlight Hims & Hers Health’s strong performance and future potential. The company reported impressive fourth-quarter results, with subscriber growth accelerating and revenue surpassing the upper end of their guidance range. This growth is supported by the continued momentum in their core specialties and the significant revenue contribution from compounded GLP-1s, which are expected to remain a substantial part of the business.
Additionally, Hims & Hers is investing in its supply chain and technological capabilities, including expanding digital capacities and integrating lab diagnostics, which should enhance their personalized offerings. The company’s forward guidance indicates robust growth, with expected revenue and EBITDA figures exceeding consensus estimates. Despite some pressure on the stock due to elevated expectations, the company’s strong execution and strategic investments present a compelling buying opportunity.
In another report released today, Needham also reiterated a Buy rating on the stock with a $61.00 price target.
Based on the recent corporate insider activity of 250 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HIMS in relation to earlier this year.